AnaptysBio, Inc.
ANAB
$43.22
-$0.54-1.23%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 146.00% | 17.21% | 10.49% | 48.39% | 11.95% |
| Total Depreciation and Amortization | 2.35% | 1.01% | 0.17% | -0.50% | 0.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 45.19% | 70.09% | 89.64% | 134.86% | 127.54% |
| Change in Net Operating Assets | -6,620.90% | -437.76% | 133.22% | -2,488.45% | 112.54% |
| Cash from Operations | -171.12% | -88.74% | 71.28% | -94.10% | 72.34% |
| Capital Expenditure | 65.71% | -18.18% | -29.63% | 6.07% | 78.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 76.10% | 1,612.74% | -78.32% | -158.90% | 90.46% |
| Cash from Investing | 76.19% | 1,590.70% | -78.36% | -159.77% | 91.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.66% | 45.35% | -64.24% | 110.23% | 61,460.63% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 96.31% | -102.01% | -69.32% | 606.51% | -743.66% |
| Cash from Financing | -114.59% | -220.55% | -109.71% | 634.35% | 2,418.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -45.28% | -399.78% | -237.86% | -808.39% | 1,443.96% |